Investors

IPO 2021 Amniotics

Facts about the IPO

Subscription period June 15 – 29, 2021.
Unit The offer consists of units. One (1) unit consists of two (2) shares and one (1) warrant of series TO 1.
Price SEK 41 per unit, corresponding to SEK 20,50 per share.
Valuation Pre-money valuation of SEK 265m.
Subscription commitments There are subscription commitments of SEK 45 million in the offer. 75 % of the offer is therefore secured.
Lock-up The total lock-up amounts to 57,8 % of the existing shares and votes in Amniotics before the transaction. The lock-up extends over 360 days from first day of trading.
Volume in the offer 1 463 415 units corresponding to SEK 60m.
Number of shares before the offer 12 935 000.
Minimum amount to subscribe 150 units, corresponding to SEK 6 150.
ISIN-code The share has ISIN-code: SE0015961016.
The warrant has ISIN-code: SE0016101471.
Marketplace Nasdaq First North Growth Market. First day of trading is estimated to take place July 6th, 2021.
Over-allotment option In order to cover a potential over-allotment in connection with the Offering, the Company has committed to issue additional new shares and warrants to a maximum of 13,3 percent of the number of units in the Offering. The Over-allotment can only be used by Lago Kapital during the first 30 days of trading on Nasdaq First North Growth Market. The Offer may, with the over-allotment option, increase with approx. SEK 8 m, corresponding to a total Offer of SEK 68 m.
Advisors Redeye is financial advisor in the offer.
Nordnet is retail selling agent in the offer.
Nordic Issuing is issuing agent in the offer.
Lago Kapital is engaged to handle stabilization of the share.
Setterwalls Advokatbyrå AB is legal advisor in the offer.

Documents

Prospekt IPO – Amniotics (.pdf, in Swedish)
Teaser IPO -Amniotics (.pdf, in Swedish)
Amniotics uppdaterade stiftelseurkund (bolagsordning) (.pdf, in Swedish)
Amniotics bolagsordning (.pdf, in Swedish)
Villkor för teckningsoptioner av serie TO 1 (.pdf, in Swedish)
Tilläggsdokument avseende listning av Amniotics AB (.pdf, in Swedish)

About Amniotics in brief

Amniotics is a biopharma company developing a broad pipeline of stem cell therapeutics based on Mesenchymal Stem Cells (MSC) from amniotic fluid. The technology is broadly applicable to major disease markets such as: Respiratory (Lung); Neurodegenerative (Brain); Nephrology (kidney); Dermatology (Skin). The Company’s first product, PulmoStem™, is focused on ARDS and ARDS related to COVID-19. The first clinical trial is planned to start in H1 ‘2022. Amniotics aim to start their second clinical trial within IPF during 2022 and their third clinical trial within Lung transplants in 2023.

The technology is based on collecting Mesenchymal Stem Cells (MSC) from amniotic fluid, followed by a patent-protected enhancement of the MSC into several kinds of tissue (or organ) specific pharmaceutical products. Amniotics controls the whole manufacturing value chain with patents covering the entire process from collection device to filling of vials.

Tissue specific MSC are believed to have improved properties for diseases affecting the organ relevant for the type of MSC. Neonatal or embryonic derived stem cells are thought to be of higher quality than those derived from adults, but sourcing in high enough quantity has been challenging (prior to new technologies such as the one from Amniotics). Amniotic-fluid based sourcing from planned C-sections provides ample supply volumes combined with high ethical standards.

The company’s founders have vast experience from research within stem cells and amniotic fluid and has since the foundation of Amniotics continued that research and development with industrial methodology. Amniotics has also invested in their GMP-certified production facility during 2020 and recruited key competences infront of the upcoming clinical studies. Amniotics plans to use MSC with lung-specific characteristics for patients with severe inflammatory and fibrotic lung diseases. To be able to execute these clinical studies, capital is needed, and the company sees a listing on Nasdaq First North Growth Market as a natural next step for Amniotics.

For more information about Amniotics, please read the prospectus.

Subscribe

Disclaimer

The information contained in this section of Amniotics AB (publ)’s (the “Company“) website contains information relating to an offer from the Company to the public to subscribe for securities in connection with the admission to trading of shares and warrants on Nasdaq First North Growth Market. This information may not be accessed by residents of certain countries based on applicable securities law regulations.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY STATE OF THE UNITED STATES INCLUDING THE DISTRICT OF COLUMBIA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

This website and the information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories and possessions), any state of the United States including the District of Columbia (the “United States“), Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, South Korea and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities in the Company in any of the above mentioned jurisdictions or in any other jurisdiction in which such offer or solicitation would be unlawful or would require registration or other measures. The securities in the Company referred to on this website have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act“), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.

All persons residing outside of the above mentioned jurisdictions who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this website.

Access to electronic versions of these materials is being made available on this website by the Company in good faith and for information purposes only.


By clicking “Confirm” you confirm and certify that:

  • You are not a resident of or physically present in any of the above jurisdictions or any other restricted jurisdiction and are not a U.S. person (as defined in Regulation S under the Securities Act); and
  • you are either:
    1. a resident of, or physically present in, Sweden;
    2. if resident or physically present in a Member State of the European Economic Area other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 of the European parliament and of the council or Article 2(e) of the Prospectus Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended and supplemented from time to time); or
    3. otherwise authorized to access this information pursuant to applicable laws or regulations.